Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2021 | 2022 | |
|---|---|---|
| Revenue | $11.2M | $25.8M |
| Cost of revenue | $10.0M | $27.6M |
| Gross profit | $1.2M | −$1.8M |
| Gross margin | 10.7% | -7.0% |
| R&D | $12.9M | $18.6M |
| Operating income | −$85.0M | −$121.8M |
| EBITDA | −$80.5M | −$121.8M |
| Net income | −$93.3M | −$55.8M |
| Net margin | -834.6% | -216.5% |
| EPS (diluted) | -16.34 | -0.79 |
Annual figures · source: Financial Modeling Prep
No one on the platform currently holds GLS.
No tracked institution reports a position in GLS as of their last filing.
No one on the platform has traded GLS yet.
| $146M |
| — |
| KRROKorro Bio, Inc. | $13.20 | +3.90% | $131M | — |
| NTBLNotable Labs, Ltd. | $0.25 | -27.68% | $2M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.